Perspectives in cancer chemotherapy 1
The first day of the two-day meeting was taken up with a symposium entitled 'Perspectives in Cancer Chemotherapy'. The first speaker, Dr Margaret Fox, (Christie Hospital & Holt Radium Institute), introduced the topic of cell kinetics and drug action. She pointed out that drugs act on different parts of the cell cycle. For instance, vinblastine has a delaying effect on cells in mitosis but it does not kill them at that point; it does, however, have a lethal effect on cells in Sand G2 phases. Dr Fox pointed out that although cell synchrony by drugs is an attractive experimental model, as yet there is no evidence for its application in patients with malignant disease. She laid considerable stress on the factors which govern the volume of the tumour after it is treated with, for example, chemotherapy. Among these are the number of cells which have been killed and the number of sterilized cells which, though sterilized, may divide more than once. Some dead cells may be cleared from the tumour, depending on the vigour of the host macrophages. The two remaining features which govern the volume of tumour after treatment are the proportion of c1onogenic cells in the tumour and the growth fraction inherent to the tumour. Dr Fox indicated the possible relevance of colony-forming unit measurement in man and the emergence over the next year or two of c1onogenic assays which, she felt, might assist us in scheduling chemotherapy.
Dr John Smyth (Department of Medicine, Royal Marsden Hospital), introduced a series of three papers on anticancer drugs. He discussed the problem of designing drugs in the laboratory for future use in the clinic. He pointed out that there is no perfect solution to the problem: either you start with an idea in the laboratory and hope that it will have clinical relevance, or else you start with a clinical" problem and turn to the laboratory to solve it. He illustrated the latter situation with the example of adenosine deaminase deficiency in combined immune deficiency children. The observation that this enzyme has a key role in lymphocyte function led to the study of it in malignant lymphocytes, where it was found to be present in very much higher concentrations than in the nor-I Report on the joint meeting of the British Association of Cancer Research and the Section of Oncology, 4-5 October 1977 0141-0768/78/0071-0619/$01.00/0 mal. Attention was then turned to designing or searching for inhibitors of adenosine deaminase. One such inhibitor, which has been successfully studied in animal systems and is now ready for phase I clinical studies, is 2-deoxycoformycin. Dr Smyth also discussed some of the problems involved in taking toxicology studies from micewhich generally can be uniformly studied in controlled experiments without complications of previous chemotherapy or concurrent therapy -to man. These problems are compounded with the ethical problems involved in introducing a new anticancer drug into the clinic. The result is the virtual exclusion of human volunteers and the necessity of testing drugs on patients who have cancer and who therefore must already have been treated by conventional chemotherapy and radiotherapy before a new drug is given. Moreover, whereas in animal toxicity studies one is trying to produce toxicity, in human studies the purpose is to define the effective dose. It may take a considerable number of different studies in different cancers and individual patient states to achieve this.
Two papers followed on the pharmacology of anti-cancer drugs by Dr Gordon McVie (University of Glasgow), and on the use of pharmacological parameters to improve response and reduce toxicity by Dr Peter Wilkinson (Christie Hospital & Holt Radium Institute). These papers covered the routes of administration of anticancer drugs, the problems of absorption of drugs from the gut and from intramuscular injection sites, and the difficulties of predicting protein binding in patients who may be depleted of proteins due to their malignant disease. The relative distribution of antitumour drugs to various compartments of the body including the tumour compartment and any other tumour-associated compartment such as pleural effusions was also discussed. It was pointed out that assays of drug in the plasma may give quite irrelevant information. The drug itself may be an inactive compound and may require to be activated, in which case the active metabolites should be measured and preferably also the enzymes required to produce the metabolites. However, even with these improvements one is still predicting from samples of the easily accessible compartment, i.e. the blood, the state of affairs in the tissues. The tissues that are of key importance are those of maximum toxicity and, of course, the tumour. Until sampling methods can be developed which facilitate repeated access to such compartments and which are acceptable from an ethical point of view, pharmacokinetics will still be limited in predicting toxicity and response.
Two contrasting papers on clinical topics were presented by Dr HEM Kay (Royal Marsden Hospital), who dealt with acute leukaemia, and Dr R D Kingston (Park Hospital, Manchester), who dealt with carcinoma of the stomach. Dr Kay reviewed the relative success story of acute lymphocytic leukaemia. He discussed the problem of privileged sites such as the central nervous system and the testis. In dealing with the prognostic factors in acute myeloid leukaemia -such as the age of the patient, cytology and chromosome abnormalities -he mentioned tissue culture studies which suggest that growth of cells in clusters is associated with a better prognosis than if numerous colonies of cells are achieved. Nevertheless, the prognosis in acute myeloid leukaemia remains persistently inferior to acute lymphocytic leukaemia.
When one turns to carcinoma of the stomach the picture is much gloomier: as Mr Kingston pointed out, even radical surgery only produces 50% survival at one year. Mr Kingston went on to describe a study which was carried out in Birmingham to evaluate 5-fluorouracil and methyl chlorethyl cyclohexyl nitrosourea in patients with advanced carcinoma of the stomach. He pointed out that out of 200 patients only 25% had evaluable lesions, so that response is extremely difficult to assess. Survival, however, was identical between the chemotherapy group and the no-treatment group, unless patients who were too ill to have up to six weeks of chemotherapy were excluded. Patients who had what he considered appropriate chemotherapy had, in fact, an improved survival over the untreated group.
Another dismal malignant disease to treat is carcinoma of the pancreas. A paper by Dr C N Mallinson (Greenwich Hospital), clearly showed that a combination of 5-f1uorouracil (5-FU) and mitomycin C at six-week intervals following an initial course of 5-FU, cyclophosphamide, vincristine and methotrexate, improved survival in 20 treated patients with carcinoma of the pancreas: median survival was II months compared with amedian survival of 3 months in control patients. He pointed out that, as with cases of carcinoma of the stomach, it was extremely difficult to stage the disease and to measure response in terms of size of the tumour despite advances in ultrasound and isotope scanning.
Two tumours which are relatively chemosensitive are carcinoma of the ovary and testicular teratoma. These were discussed by Dr Eve Wiltshaw (Royal Marsden Hospital) and Dr T J McElwain (Royal Marsden Hospital). In ovarian carcinoma, Dr Wiltshaw advocated radical surgery wherever possible followed, in the advanced case, by chemotherapy. She showed that even if surgical removal is inadequate or impossible, combination chemotherapy -particularly involving the recently developed drug cis-platinum -could achieve good response rates (approximately 60%) and good quality survival. The combinations which include platinum were, however, found to be quite toxic and particular care had to be taken to ensure adequate renal excretion. When high doses of drug were given, forced diuresis was mandatory to avoid nephrotoxicity, but higher response rates were being seen even in recurrent cases. Dr McElwain speaking on testicular teratomas, pointed out the difference between stage II disease which was bulky (lIB in his definition) and stage II with minimal lymph node involvement (IIA) which could usually be cured with radiation. The outlook for patients with stage lIB disease was, he claimed, extremely poor if radiation treatment alone was given, since there was usually failure to control the abdominal disease and this was associated with later widespread dissemination. For this reason, in his practice radiotherapy is used for treating residual disease after chemotherapy has been given, both to reduce the bulk of the abdominal disease and to deal with any potential micrometastatic tumour. He described the progression of chemotherapeutic regimens for teratoma from vinblastine and actinomycin to vinblastine, actinomycin, methotrexate plus or minus bleomycin and eventually to high dose vinblastine with five day infusions of bleomycin. The last combination has proved very successful in its induction of remissions. Provided these remissions are complete, prolonged survival follows regardless of the bulk of the disease. Patients with very bulky disease, however, fail to remit more often than those with smaller volumes of disease, and patients who only achieve partial response, or those whose response reverts inbetween courses of treatment, do not on the whole have a significantly prolonged lifespan.
A section of the afternoon was set aside for discussion of new anticancer drugs. The subject was introduced by Professor W C J Ross (Chester Beatty Research Institute), who reviewed the last 30 years of research at the Institute on the design of new anticancer drugs. He described the theory of alkylation by bifunctional agents and the design and testing of numerous agents with appropriate bifunctional alkylating properties. Dr D E V Wilman (Chester Beatty Research Institute) described chemically-stable analogues of dacarbazine (DTIC). He drew attention to the disadvantages of DTlC, in particular its major problems which are acute photosensitivity and rapid breakdown. It is possible that the toxicity commonly associated with this drug may be due to the breakdown products rather than the active drug itself. He also dealt with hexamethylmelamine and pointed out that this drug has little activity in the routine animal tumour-screening programmes and, in fact, only shows significant activity in the ADJjPC6A plasmacytoma. When the drug was tested in the human xenograft model, however, it showed marked activity against lung, ovary, colon and kidney tumours. He mentioned that pentamethylmelamine is being investigated and has possible potential as a clinical agent with greater solubility than hexamethylmelamine.
Dr John Roberts (Institute of Cancer Research) sketched in the history of the platinum compounds describing their chance discovery and going on to point out the variations on their square, planar, neutral configuration. The nomenclature of this group of compounds seems to be particularly confusing and varies from one side of the Atlantic to the other. There would appear to be a marked need for standardization of nomenclature. The principle toxicity of the group of compounds is on the kidney, and the main group of tumours in which they have shown cytotoxic activity have been tumours of the testicle, ovary, bladder, head and neck, lymphoma, prostate and, perhaps, neuroblastoma. The parent compound, cis Pt(II) diamine dichloride (cis Pt(II» had no effect whatever on acute lymphatic leukaemia or colorectal tumours in contradistinction to one of the recently prepared derivatives, platinum (II) I, 2 diaminocyclohexane malonate (PHM), which seems to be considerably less toxic than cis Pt(II) and does seem to have a different spectrum of activity including acute leukaemia and colon tumours.
Dr John Patterson (Imperial Chemical Industries) described the antioestrogen tamoxifen, and explained the theory of oestrogen receptors in breast cancer tumours and the experimental work of Lippman on the antioestrogenic effect of the drug. He reviewed the world literature on its use in advanced breast cancer in women and concluded that overall a 32% response rate (partial plus complete response) was proved, and that the length of response tended to be of the order of a year. Responses were particularly good in soft tissue disease. The outstanding attribute of the drug apart from its efficacy is that it is extremely nontoxic. In his group of over 1000 patients, only 2.7% of them stopped taking the drug because of its side effects.
Two radiosensitizing compounds were discussed: razoxane (ICRF 159) by Dr Marie Bakowski (St Bartholomew's Hospital) and R. O.
07582, misonidazole by Dr S Dische (for Professor G E Adams, Institute of Cancer Research).
Misonidazole is a trichomonicide like its sister compound metronidazole (Flagyl) though it is more neurotoxic than metronidazole. At high concentrations it can cause convulsions and at lower concentrations it has been associated with peripheral neuropathy. Its side effects are schedule dependent and in initial trials it would appear to fulfil its early promise as a radiosensitizer. Clinical trials are in progress. Dr Dische mentioned that in one patient in whom they had carried out a drill biopsy of the breast some hours after giving misonidazole, tissue levels of 80% of the plasma level had been achieved. Dr Bakowski dealing with razoxane, or ICRF 159, described laboratory studies which showed that in the L 1210leukaemia in mice it was a synergistic compound with numerous cytotoxic drugs, the principle exception being methotrexate. It also seems to be schedule dependent and has generally been given either weekly or for 3 days every 2-3 weeks. The latter mode of administration seems to produce more toxicity but also has more effect. Early clinical reports suggested some efficacy as a single agent in colorectal cancer and in Kaposi's sarcoma. In one short series of non-Hodgkin's lymphoma patients who were resistant to conventional therapy, 30% achieved complete or partial responses on razoxane administered as a single agent. Preliminary data on a trial of the drug in advanced and refractory acute leukaemias was reported.
Alexander Haddow Memorial Lecture
The highlight of the symposium was a tribute to Sir Alexander Haddow by Sir Peter Medawar. He gave as an inaugural memorial lecture, a polished, witty account of the history of tumour immunity. He took his audience back to before the turn of the century when immunity to tumours had been confused with ordinary immunity to tissue transplantation. With the development of inbred strains of mice, it then became possible to show that tumour-specific antigens did exist and that cell-mediated immunity was demonstrable against them. Sir Peter outlined the theories of immune surveillance and explained how the theory was weakened by work showing that nude mice were as resistant to chemically-induced tumours as their fully immunocompetent litter mates. Finally, he discussed in some detail the importance of anaplasia in the development of tumours. He illustrated the relevance of anaplasia by referring to the emergence of oncofetal antigens such as carcinoembryonic antigen, alphafetoprotein, and certain embryo-like characteristics of transfer RNAse and lactic dehydrogenase enzymes and hexachlorocyclohexane (ABH) precursors. He described studies which showed that fetal transplants protected animals from methylcholanthrene induced carcinogenesis. Sir Peter concluded his memorial lecture by paying a personal tribute to the work of Sir Alexander Haddow, and expressed regret for the impoverishment of cancer research caused by Sir Alexander's death.
Proferred papers
The second day of the meeting comprised two sessions of short scientific papers given by members of the Society. The communication from Dr K Sikora and Dr P L Stern was relevant to Sir Peter Medawar's remarks on oncofetal antigens. Having shown that tumour-specific transplantation antigens could be solubilized and partly characterized from methylcholanthrene-induced sarcomas in mice, they went on to show that effective immunization against these tumours could be achieved with embryonal carcinoma cells or even endodermal cells from embryoid bodies. Also on this theme of tumour-specific antigens was a negative report presented by Dr M V Pimm and Dr A J Cook. They disputed the current evidence that neuraminidase treatment of cells can decrease their tumorigenicity. The model they employed was a study of vibrio cholerae neuraminidase treatment of 7 rat tumours. In each situation neither the incidence nor the growth rate was altered by so treating the tumour cells. Another negative study on fetal antigen in human lung cancer which is, nevertheless, important, was presented by Dr C H J Ford et al. Having raised antifetal antisera they were unable to show cross reactivity with normal human cells or human lung cancer cells. There are, however, tumour antigens on lung cancer cells which would appear to be specific and not related to derepression of fetal genes. Two methodological papers were given: the first, by Dr J J Smith and Dr J A V Pritchard, concerned the demonstration of lymphocyte sensitization by a partition assay which employs tanned sheep red cells. The second, by Dr R A Robins et al., dealt with the application of the complement (C,Q) binding assay to detect immune complexes in the plasma of patients with breast cancer. This study indicated that elevated levels of immune complexes might be associated with a poor prognosis. Dr B M Vose et al. reported on the application of an old technique to a new situation. This group have looked at lymphocyte cytotoxicity against tumour cells in patients who have malignant disease. What is of interest is that they were able to pick up cytotoxic lymphocytes in peripheral blood and draining lymph nodes as long as there was no tumour infiltrating the lymph nodes. Lymphocytes derived either from the tumour or from tumourinvaded lymph nodes were nonreactive against autologous biopsy cells. This is of clinical interest in the debate on removal of lymph glands associated with primary malignancy. There is a school of thought which has for some time claimed that lymph nodes which are not involved with tumour are best left behind, whereas those which have evidence of metastatic disease within them are no longer of value to the patient and are best removed or irradiated.
Two papers on the measurement of hormones in •association with malignancy were presented. The first, by Dr G Williams et al., showed that immunodeficient female mice aged 17 weeks had significantly low levels of progesterone and oestradiol. Male animals of the same age had normal hormone values although at an earlier stage, age 9 weeks, they had low testosterone levels and high progesterone levels. The second of these papers was given by Dr J Maxwell Anderson et al. who showed that plasma oestradiol was significantly lowered in 7 postmenopausal stage II breast cancer patients during 5 day treatments with oral melphalan. During similar treatments to 6 premenopausal stage II patients, the plasma oestradiol was also lowered but not significantly. Chemotherapy may, in some instances, be improved by giving hormone therapy as appears to be indicated by the use of prednisolone with alkylating agents and the addition of steroids to conventional chemotherapy for lymphoma and myeloma. Dr R Wilkinson and Dr K R Harrap produced a follow up to their previous work presented to the British Association of Cancer Research on the mechanism of synergy between prednisolone and alkylating agents. They explained that using the Walker carcinosarcoma in rats, prednisolone added to mustine reduced toxicity and improved response rates particularly in an alkylating agent resistant tumour line, whereas melphalan toxicity was increased by prednisolone with an increase in therapeutic effect in resistant strains. It is interesting to note that in tumours sensitive to melphalan no advantage is gained by the addition of prednisolone. The interplay of steroids and alkylating agents is scheduledependent and should assist in the planning of treatment programmes in the clinic. Another interesting interaction with a chemotherapeutic agent was reported by Dr J E Morgan et al. They looked at the interaction of hyperthermia and bischloroethyl-nitrosourea (BCNU) in the EMT6 mouse tumour. After anaesthetizing the mouse with pentobarbitone, the tumour was heated in a 43°C waterbath by immersion of the tumour-bearing limb. Clear potentiation ofchemotherapy was noted in the heated animals. Results indicated that heat caused a direct increase in the cytotoxicity of BCNU and that interference with any recovery mechanism operating over the 24-hour period after treatment was not the primary factor involved. Previous in vitro studies by other workers have shown potentiation by hyperthermia with several agents, notably adriamycin, bleomycin and misonidazole. On the topic ofcarcinogenesis there was a dearth of new papers; however, two communications from Dr I Lasnitzki and Dr D R Bard filled the deficit. They have screened a large number of analogues of retinol, the naturally-occuring vitamin A, and of retinoic acid for their anticarcinogenic properties and for toxicity in organ culture. Methylcholanthrene-induced precancerous changes in mouse prostate glands were used as a model to study the influence of the analogues on carcinogenesis, and the system used to predict toxicity was the degradation of rabbit ear cartilage measured by the release oflabelled sulphate. Most of the analogues tested seem equally effective or more effective than retinol or retinoic acid in inhibiting or reversing carcinogenesis. The toxicity of the compounds is related to their structure and is highest in analogues bearing a terminal carboxyl group. Some compounds of low toxicity retained their anticarcinogenic activity.
Studies of the effect of cytotoxic drugs in tumour cultures have been fraught with problems of interpretation and practicality. Dr D Morgan and Dr R I Freshney have persisted with the study of one tumour, the human astrocytoma, and appear to have a reproducible and reliable system for predicting sensitivity of cytotoxic drugs. They have adapted a scintillation autofluorographic method to measure the levels of S35 methionine on a Kodak X-ray film. This has allowed a considerable acceleration of the method and it now has applications for treatment of individual patients. Dr I W Taylor and Dr N M Bleehen reported a study of razoxane in the EMT6 cell line and described the fascinating discovery of a stable polyploid cell line which was cloned from treated cells. It would appear that only a 24 hour exposure to razoxane is enough to double the nuclear DNA content of the cell which eventually yields the polyploid line. There appears to be a comparable response between these cells and the parent EMT6 line to radiotherapy and to further exposure to razoxane.
Amongst the clinical papers presented were two on assay ofdrugs in plasma of patients with cancer, Dr P Workman et al. 'described a high pressure liquid chromatography assay for misonidazole, a radiosensitizer currently under study, and Dr H W Van den Berg reported on a gas-liquid chromatography electron capture assay which measures 5-fluorouracil, and one of its catabolites 5-6 dihydrofluorouracil. Whether either of these last two compounds are active as cytotoxic agents remains to be shown. On the subject of 5-fluorouracil, there is still considerable debate as to the major mode of action of this drug or its metabolites. The classical teaching has been that its metabolite, 5-fluorodeoxyuridine monophosphate, inhibits thymidilate synthetase, but there is a growing body of evidence which suggests that it may have a more important inhibitory effect on RNA synthesis. An extremely elegant method has been evolved which might be used to unravel this problem. It is the simultaneous estimation of RNA and DNA in individual cells stained with acridine orange which are analysed in a flow cytofluorimetric system Dr J V Watson et at. have used these methods to estimate the nucleic acid levels throughout the cell cycle in populations of synchronized cells. Further, they have managed to distinguish different nucleic acid patterns in clonogenic and non-c1onogenic cells which may have considerable relevance in the fields of cell kinetics, drug action on cells and methods of response of tumour cells to drugs.
Finally, there were three preliminary communications: two on promising results in chemotherapy in two human tumours, and one concerning an animal model. The last was concerned with lymphoma reported in a herd of pigs and was presented by Miss S E Brownlie et al. They have now clearly shown that this is a good model for prediction of the effect of single chemotherapeutic agents in human lymphoma. Dr M Soukop et al. have reported several partial responses in disseminated malignant melanoma with a four-drug regime of adriamycin, cyclophosphamide, vincristine and prednisolone. Out of 10 evaluable patients there were 6 partial responses. This was a considerable improvement on the previous regimes used by that group which consisted of imidazole carboxamide and methyl chlorethyl cyclohexyl nitrosourea. The final paper, which was on the treatment of adult acute leukaemia, was given by Professor Hellman, the President of the Section of Oncology of the Royal Society of Medicine. He spoke about the promising combination of cytarabine and razoxane, a nontoxic regime which achieved responses in 8 out of II patients.
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